SIGN UP
LOG IN
News
INAB
1.070
+1.90%
0.020
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio, Inc. Is a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies. William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on April 18th.
Barchart · 3d ago
Weekly Report: what happened at INAB last week (0408-0412)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 6d ago
Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform
TipRanks · 04/12 05:45
ATUS, ATHE and GRFS among pre-market losers
On the Move ATUS, ATHE and GRFS among pre-market losers. Aptevo Therapeutics (APVO) -55% on pricing public offering. Carmax (KMX) -9% after Q4 earnings release. Altice USA, Inc. (ATUS) and Grifols SA (GRFS) in the red.
Seeking Alpha · 04/11 12:16
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), PainReform (PRFX) and IN8bio (INAB)
TipRanks · 04/10 16:50
IN8bio Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Dow Jones · 04/10 15:01
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $14 Price Target
Benzinga · 04/10 14:51
Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential
IN8bio Inc (NASDAQ:INAB) revealed new preclinical data from its non-signaling CAR-T cell platform. InB-300 improved selectivity to target leukemia cells while preserving healthy ones. INAB stock went up as much as 9% in the premarket session.
Benzinga · 04/10 14:38
IN8bio gains after new preclinical data for nsCAR-T cell therapy platform
Shares of IN8bio rose about 5% on Wednesday. The company reported new preclinical data that supports the potential for the proprietary nsCAR-T cell therapy platform to selectively eliminate cancer cells while preserving healthy tissue. INAB +11.00% premarket to $1.21.
Seeking Alpha · 04/10 13:49
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
PriceSmart, Inc. Posted better-than-expected earnings for its second quarter. The company reported quarterly sales of $1.29 billion. PriceSmart shares surged 4.6% to $86.90 in pre-market trading. Marin Software Incorporated shares rose 76.1% after the company announced upgrades to its Microsoft Corp advertising integration.
Benzinga · 04/10 12:12
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
IN8bio stock increased by 47.7% to $1.61 during Wednesday's pre-market session. Jaguar Health (NASDAQ:JAGX) shares rose 25.0% during the session. China SXT Pharmaceuticals shares moved upwards by 24.85%. Losers in the market were BioSig Technologies and Kineta.
Benzinga · 04/10 12:09
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Marin Software (NASDAQ:MRIN) stock is rocketing more than 67% after upgrading its integration with Microsoft Advertising. Shareholder meetings, clinical updates, an annual report and delisting plans are moving stocks this morning. The biggest pre-market stock movers on Wednesday morning are Marin Software and iCoreConnect.
Investorplace · 04/10 11:28
Stocks to Watch: Smart Global Holdings, Velo3D, IN8bio
Smart Global Holdings posts a wider-than-expected loss in the fiscal second quarter. Velo3D says it will sell stock and warrants in a public offering. IN8bio says preclinical data on its potential cancer treatment shows improved ability to kill leukemia cells.
Dow Jones · 04/09 23:18
IN8bio Shares Pop 32% on Early Cancer Treatment Data
Shares of IN8bio rose 32% to $1.44 in late trading. The company says preclinical data on its potential cancer treatment shows it may be able to avoid killing healthy cells. The stock is down 21% since the start of the year. The biopharmaceutical company says its technology could target leukemia cells while leaving healthy ones alone.
Dow Jones · 04/09 23:09
IN8BIO ANNOUNCES NEW PRECLINICAL DATA FOR GAMMA-DELTA NSCAR-T CELL THERAPY PLATFORM AT AACR 2024
Reuters · 04/09 20:30
Weekly Report: what happened at INAB last week (0401-0405)?
Weekly Report · 04/08 09:38
Weekly Report: what happened at INAB last week (0325-0329)?
Weekly Report · 04/01 09:38
Weekly Report: what happened at INAB last week (0318-0322)?
Weekly Report · 03/25 09:39
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Intuitive Surgical (ISRG) and IN8bio (INAB)
TipRanks · 03/19 06:21
More
Webull provides a variety of real-time INAB stock news. You can receive the latest news about In8Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.